ACC International Holdings Ltd. 4

4 · BRAINSTORM CELL THERAPEUTICS INC. · Filed Jul 16, 2020

Insider Transaction Report

Form 4
Period: 2020-07-09
Transactions
  • Sale

    Common Stock

    2020-07-16$13.47/sh7,823$105,35167,053 total
  • Sale

    Common Stock

    2020-07-09$13.13/sh3,500$45,939135,306 total
  • Sale

    Common Stock

    2020-07-10$13.35/sh2,000$26,700133,306 total
  • Sale

    Common Stock

    2020-07-13$13.52/sh40,000$540,95293,306 total
  • Sale

    Common Stock

    2020-07-15$13.12/sh18,430$241,71574,876 total
Footnotes (4)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.0816 to $13.1581, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.338 to $13.61, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.1 to $13.15, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.46 to $13.4684, inclusive. The Reporting Person undertakes to provide to the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Documents

1 file
  • 4
    tm2024939d1_4.xmlPrimary

    OWNERSHIP DOCUMENT